Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis

被引:7
|
作者
Poonam, Jain P. [1 ]
Mayur, Parihar [3 ]
Rayaz, Ahmed [2 ]
Aby, Abraham [2 ]
Auro, Vishwabandya [2 ]
Biju, George [2 ]
Vikram, Mathews [2 ]
Alok, Srivastava [2 ]
Vivi, Srivastava M. [1 ]
机构
[1] Christian Med Coll & Hosp, Cytogenet Unit, Vellore 632004, Tamil Nadu, India
[2] Christian Med Coll & Hosp, Dept Hematol, Vellore 632004, Tamil Nadu, India
[3] Tata Med Ctr, Dept Cytogenet, Kolkata, W Bengal, India
关键词
Chronic myelogenous leukemia; BCR/ABL1; fusion; atypical FISH signals; CHRONIC-MYELOID-LEUKEMIA; D-FISH PATTERNS; DERIVATIVE CHROMOSOME-9; VARIANT TRANSLOCATIONS; CYTOGENETIC RESPONSE; GENE REARRANGEMENTS; PERIPHERAL-BLOOD; CLONAL EVOLUTION; CML; DELETIONS;
D O I
10.4103/0377-4929.101742
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Chronic myelogenous leukemia (CML) is characterised by the t(9;22)(q34;q11.2) which results in the formation of the BCR/ABL1 fusion gene. Occasionally, the t(9;22) may be associated with submicroscopic deletions of chromosomes 9 and/or 22 which appear to be associated with a worse prognosis. Three or four-way variant t(9;22) may also occur. All these changes as well as gain of the Philadelphia chromosome which represents disease progression can be detected by fluorescence in situ hybridization (FISH) analysis. FISH analysis at presentation is used to determine the number of cells with BCR/ABL1 fusion and establish whether the patterns are typical or atypical. Response to therapy can then be monitored by serial testing. Patients and Methods: The study group consisted of all patients diagnosed or suspected to have CML who had interphase FISH analysis at presentation on peripheral blood/bone marrow using a commercially available BCR/ABL1 dual colour, dual fusion probe. The study was performed at a tertiary hospital in India between 2004 and 2010. Results: There were 1076 diagnostic samples which were positive for BCR/ABL1 fusion. Typical dual fusion signals (two fusions, one red and one green, 2F1R1G) were seen in 801 cases (74 %). Atypical signal patterns were seen in 275 cases (26%). These were: 1F1R2G (4%), 1F2R1G (2.5%) and 1F1R1G (11%) representing deletions of the derivative 9 involving chromosome 9 sequences, chromosome 22 sequences, or both respectively; 3F1R1G (6.5%) usually representing gain of an additional Philadelphia chromosome and 1F2R2G (1%) representing a three-or four-way variant translocation. More than one signal pattern was seen in 1%. Conclusions: Our findings were similar to the literature with respect to the distribution of signal patterns except that we had a lower number of patients with variant translocations. While each signal pattern is typically associated with a particular abnormality, there can be more than one explanation for each pattern. Hence, metaphase FISH analysis is the "gold standard" for the interpretation of signal patterns.
引用
收藏
页码:347 / 351
页数:5
相关论文
共 50 条
  • [31] DETECTION OF BCR-ABL FUSION IN CHRONIC MYELOGENEOUS LEUKEMIA BY INSITU HYBRIDIZATION
    TKACHUK, DC
    WESTBROOK, CA
    ANDREEFF, M
    DONLON, TA
    CLEARY, ML
    SURYANARAYAN, K
    HOMGE, M
    REDNER, A
    GRAY, J
    PINKEL, D
    LABORATORY INVESTIGATION, 1991, 64 (01) : A85 - A85
  • [32] Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia
    Zhanglin Zhang
    Zhiwei Chen
    Mei Jiang
    Shuyuan Liu
    Yang Guo
    Lagen Wan
    Fei Li
    BMC Cancer, 19
  • [33] Methylation of the ABL1 promoter in chronic myelogenous leukemia:: Lack of prognostic significance
    Issa, JPJ
    Kantarjian, H
    Mohan, A
    O'Brien, S
    Cortes, J
    Pierce, S
    Talpaz, M
    BLOOD, 1999, 93 (06) : 2075 - 2080
  • [34] Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia
    Zhang, Zhanglin
    Chen, Zhiwei
    Jiang, Mei
    Liu, Shuyuan
    Guo, Yang
    Wan, Lagen
    Li, Fei
    BMC CANCER, 2019, 19 (01)
  • [35] Frequency of BCR-ABL Fusion Transcripts in Saudi Patients with Chronic Myelogenous Leukemia
    Elbjeirami, W. M.
    Abdulwahab, A.
    Elsayed, H.
    Elnagdi, N.
    Abd Allatif, N.
    Al-Jedani, H.
    Al Shaikh, A.
    Al-Allaf, F. A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 766 - 766
  • [36] Cytogenetic, fluorescence in situ hybridization, and genomic array characterization of chronic myeloid leukemia with cryptic BCR-ABL1 fusions
    Shao, Lina
    Miller, Sue
    Keller-Ramey, Jennifer
    Zhang, Yang
    Roulston, Diane
    CANCER GENETICS, 2015, 208 (7-8) : 396 - 403
  • [37] ACTIVATION OF BCR-ABL FUSION GENE AND RAS ONCOGENES IN CHRONIC MYELOGENOUS LEUKEMIA
    FUTAKI, M
    INOKUCHI, K
    DAN, K
    NOMURA, T
    LEUKEMIA & LYMPHOMA, 1991, 5 (2-3) : 163 - 169
  • [38] Prevalence of the BCR/ABL1 transcripts in Mexican patients with chronic myelogenus leukemia
    Pablo Meza-Espinoza, Juan
    Gutierrez-Angulo, Melva
    Vazquez-Cardenas, Alejandra
    Luis Delgado-Lamas, Jose
    Amparo Esparza-Flores, Maria
    Ramon Gonzalez-Garcia, Juan
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2007, 59 (05): : 338 - 341
  • [39] Distribution of BCR–ABL1 Transcript Variants in Nigerians with Chronic Myeloid Leukemia
    Temilola O. Owojuyigbe
    Muheez A. Durosinmi
    Ramoni A. A. Bolarinwa
    Lateef Salawu
    Norah O. Akinola
    Abdulwaheed A. Ademosun
    Oluwayomi T. Bosede
    Indian Journal of Hematology and Blood Transfusion, 2020, 36 : 646 - 651
  • [40] Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with BCR::ABL1 fusion
    Mizuno, Shohei
    Takami, Akiyoshi
    Kawamura, Koji
    Harada, Kaito
    Masayoshi, Masuko
    Yano, Shingo
    Ito, Ayumu
    Ozawa, Yukiyasu
    Ouchi, Fumihiko
    Ashida, Takashi
    Nawa, Yuichiro
    Ichinohe, Tatsuo
    Fukuda, Takahiro
    Atsuta, Yoshiko
    Yanada, Masamitsu
    EJHAEM, 2024, 5 (02): : 369 - 378